Semler Scientific, Inc. Announces Major Clinical Study Using Semler's QuantaFlo® for Medicare Advantage Beneficiaries, Demonstrates that National, In-Home Screening for Peripheral Artery Disease is Feasible
December 14, 2022 at 08:03 am EST
Share
Semler Scientific, Inc. announced that a study was published in the peer-reviewed AJPM Focus with data collected using the company's QuantaFlo® PAD test under real-world conditions, illustrating the benefits of PAD in-home screening. AJPM Focus is the official open access journal jointly launched this year by both The American College of Preventive Medicine and the Association for Prevention Teaching and Research. The study analyzed screening tests using QuantaFlo® for Medicare Advantage beneficiaries aged =65 years participating in the Optum HouseCalls program in the U.S. between April 1, 2017 and February 1, 2019. Of the 192,500 patients tested in their homes, 27.7% had a positive result for PAD. One-year all-cause mortality, 1- and 2-year major adverse cardiovascular events (MACE), and major adverse limb events (MALE) in the PAD positive patients were all significantly increased versus those patients who screened negative for PAD (p <.001).
Moreover, the severity of the test results was associated with worse outcomes. This study provides evidence for the feasibility of a nationwide PAD-screening program with QuantaFlo® for individuals aged 65 years and older to assess previously undetected PAD burden, which can enable further stratification of all-cause mortality, MACE, and MALE risk. The authors stated, "Detecting previously undiagnosed peripheral artery disease is a way to risk stratify a population that would benefit from further cardiovascular risk management".
Semler Scientific, Inc. develops, manufactures, and markets products and services that assist in evaluating and treating chronic diseases. The Company provides technology solutions to healthcare providers. The Company's flagship product, QuantaFlo is a four-minute in-office blood flow test. Healthcare providers can use blood flow measurements as part of their examinations of a patientâs vascular condition, including assessments of patients who have vascular disease. QuantaFlo features a sensor clamp that is placed on the toe or finger. Infrared light emitted from the clamp on the dorsal surface of the digit is scattered and reflected by the red blood cells coursing through the area of illumination. Returning light is sensed by the sensor. A blood flow waveform is instantaneously constructed by its proprietary software algorithm. Its customers for QuantaFlo include insurance plans, physician groups, risk assessment groups, hospitals and retailers.
Semler Scientific, Inc. Announces Major Clinical Study Using Semler's QuantaFlo® for Medicare Advantage Beneficiaries, Demonstrates that National, In-Home Screening for Peripheral Artery Disease is Feasible
SEMLER SCIENTIFIC, INC. 
